STOCK TITAN

Avista Healthcare Partners Announces Promotions

Avista Healthcare Partners (ORGO) announced on January 5, 2026 three promotions within its investment team: Ryan Moran and Garrett Lustig were promoted to Partner, and Elaine Tang was promoted to Principal.

(Neutral)
(Very Positive)
Tags

Avista Healthcare Partners (ORGO) announced on January 5, 2026 three promotions within its investment team: Ryan Moran and Garrett Lustig were promoted to Partner, and Elaine Tang was promoted to Principal.

The announcement highlights each executive's tenure and background: Moran joined Avista in 2018 with prior roles at Morgan Stanley Capital Partners and Bank of America Merrill Lynch; Lustig joined in 2015 from Centerview Partners; Tang joined in 2022 from Partners Group. Each exec currently serves on multiple portfolio company boards, including Organogenesis (Nasdaq: ORGO) for Lustig.

David Burgstahler, CEO, said the promotions reflect Avista's growth and focus on developing leadership as the firm pursues healthcare investment opportunities.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.
Argus Jan 5 session
-4.85% close to close Open Argus
Details

News Market Reaction – ORGO

In the Jan 5 session, ORGO declined 4.85%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights leadership depth at Avista, one of ORGO’s key stakeholders, with Avista...
Analysis

This announcement highlights leadership depth at Avista, one of ORGO’s key stakeholders, with Avista executives continuing to serve on Organogenesis’s Board. In the past six months ORGO has advanced a BLA for ReNu, reported record Q3 revenue, and navigated reimbursement and governance developments. Investors may watch for future updates on ReNu’s regulatory path, Medicare coverage changes effective January 1, 2026, and any further Board or ownership disclosures.

Key Figures

Promotion count: 3 promotions Ryan Moran tenure: Joined 2018 Garrett Lustig tenure: Joined 2015 +1 more
Promotion count
3 promotions
Three Avista investment professionals elevated (two to Partner, one to Principal)
Ryan Moran tenure
Joined 2018
Year Ryan Moran joined Avista before promotion to Partner
Garrett Lustig tenure
Joined 2015
Year Garrett Lustig joined Avista before promotion to Partner
Elaine Tang tenure
Joined 2022
Year Elaine Tang joined Avista before promotion to Principal

Historical Context

5 past events · Latest: Dec 23
5 events
  1. Dec 23

    Regulatory filing update

    24h Move
    +2.1%

    Rolling BLA submission for ReNu with final modules expected in 1H 2026.

  2. Dec 15

    Regulatory meeting news

    24h Move
    +0.2%

    Successful FDA Type-B meeting and plan to initiate rolling BLA for ReNu.

  3. Nov 06

    Earnings and guidance

    24h Move
    -2.0%

    Record Q3 revenue, higher profitability, and raised FY2025 revenue and EBITDA guidance.

  4. Nov 03

    Reimbursement policy news

    24h Move
    -5.9%

    CMS finalized skin substitute payment reform viewed as supportive for PMA products.

  5. Oct 31

    Equity compensation grants

    24h Move
    -5.9%

    Inducement stock options and RSUs granted to new CTO under Nasdaq Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced three key promotions within its investment team, reflecting the firm's continued growth and commitment to developing top talent.

  • Ryan Moran has been promoted to Partner;
  • Garrett Lustig has been promoted to Partner; and
  • Elaine Tang has been promoted to Principal.

David Burgstahler, Managing Partner and Chief Executive Officer of Avista, commented:
"We are thrilled to recognize Ryan, Garrett, and Elaine for their outstanding contributions to Avista's success as well as their partnerships with our portfolio company management teams and Boards. The firm's growth and continued development of our team underscore the depth and strength of the firm's leadership team. We look forward to their leadership as we pursue new and compelling investment opportunities in the healthcare sector."

Ryan Moran: Ryan joined Avista in 2018. Prior to joining Avista, he was an Associate at Morgan Stanley Capital Partners where he focused on private equity investments across a range of industries. Prior to joining Morgan Stanley, he worked as an Analyst in the investment banking division at Bank of America Merrill Lynch. Ryan received a B.A. from The George Washington University and an M.B.A. from Harvard Business School. He currently serves as a Director of Cosette Pharmaceuticals, GCM Holding Corporation, WellSpring Consumer Healthcare, and XIFIN.

Garrett Lustig: Garrett joined Avista in 2015. Prior to joining Avista, he worked in investment banking at Centerview Partners. Garrett received a B.S. from Duke University. He currently serves as a Director of ACP Northern Holdings, EBi Bone Healing, eMolecules, Organogenesis (Nasdaq: ORGO), Taconic Biosciences, and Terrats Medical and previously served as a Director of Solmetex, Spear Education, United BioSource Corporation, and XIFIN.

Elaine Tang: Elaine joined Avista in 2022. Prior to joining Avista, she worked in private equity at Partners Group. Elaine received a B.A. from Wellesley College and an M.B.A. from Harvard Business School. She currently serves as a Director of PK Benelux and Probo Medical.

About Avista Healthcare Partners

Avista Healthcare Partners, founded in 2005 by Thompson Dean and David Burgstahler, is a leading New York-based private equity firm with over $10 billion invested in more than 50 growth-oriented healthcare businesses globally. Avista partners with businesses that feature strong management teams, stable cash flows and robust growth prospects – targeting healthcare product and technology businesses with clear scale potential across four sub-sectors experiencing strong tailwinds. The team is supported by a group of seasoned Strategic Executives enhancing the entire investment process through strategic insight, long-term value and sustainable businesses. For more information, visit www.avistahealthcare.com or follow Avista on LinkedIn.

For media inquiries, please contact:
Daniel Yunger / James Lindsay
Kekst CNC
daniel.yunger@kekstcnc.com / james.lindsay@kekstcnc.com
917.574.8582 / 917.842.4119

Cision View original content:https://www.prnewswire.com/news-releases/avista-healthcare-partners-announces-promotions-302652569.html

SOURCE Avista Healthcare Partners

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who was promoted at Avista Healthcare Partners on January 5, 2026 (ORGO)?

Avista promoted Ryan Moran and Garrett Lustig to Partner and Elaine Tang to Principal.

What backgrounds do the promoted Avista leaders have and how long have they been at the firm?

Moran joined in 2018 from Morgan Stanley Capital Partners; Lustig joined in 2015 from Centerview Partners; Tang joined in 2022 from Partners Group.

Does Garrett Lustig serve on the board of any public company such as Organogenesis (ORGO)?

Yes, Garrett Lustig currently serves as a Director of Organogenesis (Nasdaq: ORGO).

What did Avista's CEO say about the January 5, 2026 promotions?

CEO David Burgstahler said the promotions reflect the firm's growth and commitment to developing leadership while pursuing new healthcare investments.

Where can investors find more information about Avista's leadership and director roles after the promotions?

Investors can review Avista's investor relations or company website for updated leadership bios and portfolio board listings.

Keep reading